Loading organizations...
§ Venture Capital · Lausanne, Vaud, Switzerland
Swiss Diabetes Venture Fund (SDVF) is the first venture fund dedicated to investing in global diabetes technology startups. It provides capital for innovations across diabetes care. The fund partners with Serpentine Ventures and Diabetes Center Berne, utilizing their networks, deal flow, and medtech knowledge to support its portfolio companies.
Launched June 14, 2021, the fund stemmed from collaboration between Swiss Startup Group AG, DCB Research AG (a Diabetes Center Berne Foundation subsidiary), and Simon Michel. This initiative recognized a burgeoning diabetes technology hub in Berne. Founders Simon Michel (Ypsomed), Derek Brandt (DCB), and Mike Baur (Swiss Startup Group) contributed deep industry and venture expertise.
SDVF’s investments target improved diagnostic and therapeutic solutions for diabetes patients. The fund's vision addresses the increasing global challenge of diabetes. By backing innovative ventures, Swiss Diabetes Venture Fund aims to accelerate impactful technology introductions, improving patient outcomes and transforming management.
Swiss%20Diabetes%20Venture%20Fund has 2 tracked investments across 2 companies. The latest tracked deal is $24.0M Series A in Luna Diabetes in August 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 1, 2025 | Luna Diabetes | $24.0M Series A | Vensana Capital | Ascensia Diabetes Care, Winklevoss Capital |
| Jul 29, 2022 | Piomic | $7.9M Series A | Swiss%20diabetes%20venture%20fund | Nest%20pension%20fund, Verve Ventures, Z%C3%BCrcher%20Kantonalbank |